FDA note data current data do not support use of leronlimab for COVID-19

In a phase III trial, this CCR5 antagonist failed to hit the primary endpoint of symptom reduction, as well as all other secondary endpoints. The FDA refused to review a subgroup analysis presented by the company stating it was exploratory only.

Source:

Biospace Inc.